“Kidney Week was extremely productive for us featuring a late-breaking presentation on our OLC pivotal trial, and our numerous data presentations were well received by the medical community ...

(“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present five ...

With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

announced that data supporting additional positive clinical observations of Xphozah was presented in a series of poster presentations at the American Society of Nephrology’s, or ASN, Kidney Week ...

Oct. 15, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced ...

If a clinician sees more than one patient with a similar presentation, “that would be another hint” that a foodborne pathogen might be responsible and to investigate kidney function.

The lesion in the upper pole of the left kidney reportedly had homogeneous enhancement and was suggestive of renal-cell carcinoma. Approximately 17 months before the current presentation ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...

Digital access Digital + home delivery TSX 0.14 % ...

Dr. Allen Davidoff, CEO of XORTX, stated, “We are pleased to once again be presenting pioneering studies in PKD due to ADPKD at the American Society of Nephrology annual meeting during Kidney Week ...